Sana Biotechnology (SANA) Assets Average (2021 - 2026)
Sana Biotechnology (SANA) posted Assets Average of $395.2 million for Q1 2026, down 7.26% sequentially from $426.2 million in Q4 2025, and down 16.48% YoY from $473.2 million in Q1 2025.
Sana Biotechnology (SANA) Assets Average (2021 - 2026) Analysis & Trends
Sana Biotechnology has reported Assets Average for 6 years, with the latest figure at $395.2 million in Q1 2026.
- Quarterly Assets Average fell 16.48% year-over-year to $395.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $395.2 million (down 16.48% YoY) and the FY2025 annual result came in at $459.0 million, down 13.92% from the prior year.
- Assets Average eased to $395.2 million in Q1 2026 per SANA's latest filing, from $426.2 million in the prior quarter.
- Over five years, Assets Average peaked at $1.1 billion in Q1 2022 and troughed at $395.2 million in Q1 2026.
- A 5-year average of $656.6 million and a median of $623.3 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average increased 6.99% in 2022, then slumped 37.92% in 2025.
- Over 5 years, Assets Average stood at $860.4 million in 2022, then slumped by 30.46% to $598.4 million in 2023, then slipped by 11.39% to $530.2 million in 2024, then fell by 19.62% to $426.2 million in 2025, then retreated by 7.26% to $395.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $395.2 million, $426.2 million, and $398.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 402.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 402.56 Mn |
| Mar 31, 2026 | 395.24 Mn |
| Dec 31, 2025 | 426.16 Mn |
| Sep 30, 2025 | 398.54 Mn |
| Jun 30, 2025 | 403.56 Mn |
| Mar 31, 2025 | 473.25 Mn |
| Dec 31, 2024 | 530.21 Mn |
| Sep 30, 2024 | 589.03 Mn |
| Jun 30, 2024 | 650.02 Mn |
| Mar 31, 2024 | 623.34 Mn |
| Dec 31, 2023 | 598.37 Mn |
| Sep 30, 2023 | 669.29 Mn |
| Jun 30, 2023 | 727.04 Mn |
| Mar 31, 2023 | 784.82 Mn |
| Dec 31, 2022 | 860.41 Mn |
| Sep 30, 2022 | 934.60 Mn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 1.09 Bn |
| Dec 31, 2021 | 1.18 Bn |
| Sep 30, 2021 | 1.25 Bn |